Adenosine receptor control of cognition in normal and disease

International Review of Neurobiology

Volumn 119, Issue , 2014, Pages 257-307

  Chen, Jiang Fan ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Huntington's disease; Learning and memory; Parkinson's disease; Schizophrenia; Synaptic plasticity

Indexed keywords

5' NUCLEOTIDASE; ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE KINASE; ADENOSINE RECEPTOR; AMYLOID BETA PROTEIN[1-42]; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CAFFEINE; DOPAMINE; DOPAMINE 2 RECEPTOR; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; GLUTAMIC ACID; INTERLEUKIN 1; INTERLEUKIN 1BETA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PROTEIN TYROSINE KINASE A; VESICULAR GLUTAMATE TRANSPORTER 1; PURINERGIC RECEPTOR AFFECTING AGENT;

AGING; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR; CELLULAR DISTRIBUTION; COGNITION; CONDITIONAL TEMPORAL PROBABILITY; EFFORT RELATED BEHAVIOR; FEAR CONDITIONING; FOOD INTAKE; GOAL DIRECTED BEHAVIOR; HABIT FORMATION; HOMEOSTASIS; HUMAN; HUNTINGTON CHOREA; INTRACELLULAR SIGNALING; LEARNING; LONG TERM DEPRESSION; LONG TERM POTENTIATION; MEMORY; MENTAL DISEASE; MOLECULAR DYNAMICS; NERVE CELL PLASTICITY; NERVE EXCITABILITY; NEUROLOGIC DISEASE; NEUROMODULATION; NEUROPATHOLOGY; NEUROPHYSIOLOGY; NEUROPSYCHIATRIC DISORDER; NONHUMAN; PARACRINE SIGNALING; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SCHIZOPHRENIA; SHORT TERM MEMORY; SYNAPTIC TRANSMISSION; WORKING MEMORY; ANIMAL; COGNITION DISORDERS; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; COGNITION; COGNITION DISORDERS; HUMANS; PURINERGIC AGENTS; RECEPTORS, PURINERGIC P1; SIGNAL TRANSDUCTION;

EID: 84906738009     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-801022-8.00012-X     Document Type: Chapter

References (336)

1. Aarsland D., Bronnick K., Williams-Gray C., Weintraub D., Marder K., Kulisevsky J., et al. Mild cognitive impairment in Parkinson disease: A multicenter pooled analysis. Neurology 2010, 75:1062-1069.
2. Abi-Dargham A., Rodenhiser J., Printz D., Zea-Ponce Y., Gil R., Kegeles L.S., et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:8104-8109.
3. Adams J.P., Sweatt J.D. Molecular psychology: Roles for the ERK MAP kinase cascade in memory. Annual Review of Pharmacology and Toxicology 2002, 42:135-163.
4. Aisen P.S., Cummings J., Schneider L.S. Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease. Cold Spring Harbor Perspectives in Medicine 2012, 2:a006395.
5. Akhondzadeh S., Shasavand E., Jamilian H., Shabestari O., Kamalipour A. Dipyridamole in the treatment of schizophrenia: Adenosine-dopamine receptor interactions. Journal of Clinical Pharmacy and Therapeutics 2000, 25:131-137.
6. Alfinito P.D., Wang S.P., Manzino L., Rijhsinghani S., Zeevalk G.D., Sonsalla P.K. Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively. Journal of Neuroscience 2003, 23:10982-10987.
7. Alhaider I.A., Aleisa A.M., Tran T.T., Alzoubi K.H., Alkadhi K.A. Chronic caffeine treatment prevents sleep deprivation-induced impairment of cognitive function and synaptic plasticity. Sleep 2010, 33:437-444.
8. Aliagas E., Villar-Menendez I., Sevigny J., Roca M., Romeu M., Ferrer I., et al. Reduced striatal ecto-nucleotidase activity in schizophrenia patients supports the "adenosine hypothesis". Purinergic Signal 2013, 9:599-608.
9. Alzoubi K.H., Srivareerat M., Aleisa A.M., Alkadhi K.A. Chronic caffeine treatment prevents stress-induced LTP impairment: The critical role of phosphorylated CaMKII and BDNF. Journal of Molecular Neuroscience 2013, 49:11-20.
10. Amanzio M., Benedetti F., Vase L. A systematic review of adverse events in the placebo arm of donepezil trials: The role of cognitive impairment. International Psychogeriatrics 2012, 24:698-707.
11. Andreasen N., Minthon L., Davidsson P., Vanmechelen E., Vanderstichele H., Winblad B., et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Archives of Neurology 2001, 58:373-379.
12. Arai A., Lynch G. Factors regulating the magnitude of long-term potentiation induced by theta pattern stimulation. Brain Research 1992, 598:173-184.
13. Arendash G.W., Mori T., Cao C., Mamcarz M., Runfeldt M., Dickson A., et al. Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged Alzheimer's disease mice. Journal of Alzheimer's Disease 2009, 17:661-680.
14. Arendash G.W., Schleif W., Rezai-Zadeh K., Jackson E.K., Zacharia L.C., Cracchiolo J.R., et al. Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production. Neuroscience 2006, 142:941-952.
15. Ascherio A., Zhang S.M., Hernan M.A., Kawachi I., Colditz G.A., Speizer F.E., et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Annals of Neurology 2001, 50:56-63.
16. Assaife-Lopes N., Sousa V.C., Pereira D.B., Ribeiro J.A., Chao M.V., Sebastiao A.M. Activation of adenosine A2A receptors induces TrkB translocation and increases BDNF-mediated phospho-TrkB localization in lipid rafts: Implications for neuromodulation. Journal of Neuroscience 2010, 30:8468-8480.
17. Assaife-Lopes N., Sousa V.C., Pereira D.B., Ribeiro J.A., Sebastiao A.M. Regulation of TrkB receptor translocation to lipid rafts by adenosine A receptors and its functional implications for BDNF-induced regulation of synaptic plasticity. Purinergic Signalling 2014, 10:2510267.
18. Augusto E., Matos M., Sevigny J., El-Tayeb A., Bynoe M.S., Muller C.E., et al. Ecto-5'-nucleotidase (CD73)-mediated formation of adenosine is critical for the striatal adenosine A2A receptor functions. Journal of Neuroscience 2013, 33:11390-11399.
19. Baddeley A.D., Bressi S., Della Sala S., Logie R., Spinnler H. The decline of working memory in Alzheimer's disease. A longitudinal study. Brain 1991, 114(Pt. 6):2521-2542.
20. Balleine B.W., Dickinson A. Goal-directed instrumental action: Contingency and incentive learning and their cortical substrates. Neuropharmacology 1998, 37:407-419.
21. Barone P., Aarsland D., Burn D., Emre M., Kulisevsky J., Weintraub D. Cognitive impairment in nondemented Parkinson's disease. Movement Disorders 2011, 26:2483-2495.
22. Benito E., Barco A. CREB's control of intrinsic and synaptic plasticity: Implications for CREB-dependent memory models. Trends in Neurosciences 2010, 33:230-240.
23. Bennett E.J., Shaler T.A., Woodman B., Ryu K.-Y., Zaitseva T.S., Becker C.H., et al. Global changes to the ubiquitin system in Huntington's disease. Nature 2007, 448:704-708.
24. Blundon J.A., Bayazitov I.T., Zakharenko S.S. Presynaptic gating of postsynaptically expressed plasticity at mature thalamocortical synapses. Journal of Neuroscience 2011, 31:16012-16025.
25. Boison D., Chen J.F., Fredholm B.B. Adenosine signaling and function in glial cells. Cell Death and Differentiation 2010, 17:1071-1082.
26. Boison D., Singer P., Shen H.Y., Feldon J., Yee B.K. Adenosine hypothesis of schizophrenia-Opportunities for pharmacotherapy. Neuropharmacology 2012, 62:1527-1543.
27. Bozdagi O., Rich E., Tronel S., Sadahiro M., Patterson K., Shapiro M.L., et al. The neurotrophin-inducible gene Vgf regulates hippocampal function and behavior through a brain-derived neurotrophic factor-dependent mechanism. Journal of Neuroscience 2008, 28:9857-9869.
28. Brozoski T.J., Brown R.M., Rosvold H.E., Goldman P.S. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science 1979, 205:929-932.
29. Cabeza de Vaca S., Kannan P., Pan Y., Jiang N., Sun Y., Carr K.D. The adenosine A2A receptor agonist, CGS-21680, blocks excessive rearing, acquisition of wheel running, and increases nucleus accumbens CREB phosphorylation in chronically food-restricted rats. Brain Research 2007, 1142:100-109.
30. Calabresi P., Maj R., Mercuri N.B., Bernardi G. Coactivation of D1 and D2 dopamine receptors is required for long-term synaptic depression in the striatum. Neuroscience Letters 1992, 142:95-99.
31. Calabresi P., Maj R., Pisani A., Mercuri N.B., Bernardi G. Long-term synaptic depression in the striatum: Physiological and pharmacological characterization. Journal of Neuroscience 1992, 12:4224-4233.
32. Canals M., Marcellino D., Fanelli F., Ciruela F., de Benedetti P., Goldberg S.R., et al. Adenosine A2A-dopamine D2 receptor-receptor heteromerization: Qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. Journal of Biological Chemistry 2003, 278:46741-46749.
33. Canas P.M., Porciuncula L.O., Cunha G.M., Silva C.G., Machado N.J., Oliveira J.M., et al. Adenosine A2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by beta-amyloid peptides via p38 mitogen-activated protein kinase pathway. Journal of Neuroscience 2009, 29:14741-14751.
34. Cao C., Cirrito J.R., Lin X., Wang L., Verges D.K., Dickson A., et al. Caffeine suppresses amyloid-beta levels in plasma and brain of Alzheimer's disease transgenic mice. Journal of Alzheimer's Disease 2009, 17:681-697.
35. Cao C., Loewenstein D.A., Lin X., Zhang C., Wang L., Duara R., et al. High blood caffeine levels in MCI linked to lack of progression to dementia. Journal of Alzheimer's Disease 2012, 30(3):559-572.
36. Cepeda C., Wu N., Andre V.M., Cummings D.M., Levine M.S. The corticostriatal pathway in Huntington's disease. Progress in Neurobiology 2007, 81:253-271.
37. Chamberlain S.E., Sadowski J.H., Teles-Grilo Ruivo L.M., Atherton L.A., Mellor J.R. Long-term depression of synaptic kainate receptors reduces excitability by relieving inhibition of the slow afterhyperpolarization. Journal of Neuroscience 2013, 33:9536-9545.
38. Chao M.V. Neurotrophins and their receptors: A convergence point for many signalling pathways. Nature Review Neuroscience 2003, 4:299-309.
39. Charalambous C., Gsandtner I., Keuerleber S., Milan-Lobo L., Kudlacek O., Freissmuth M., et al. Restricted collision coupling of the A2A receptor revisited: Evidence for physical separation of two signaling cascades. Journal of Biological Chemistry 2008, 283:9276-9288.
40. Chaudhuri K.R., Schapira A.H. Non-motor symptoms of Parkinson's disease: Dopaminergic pathophysiology and treatment. Lancet Neurology 2009, 8:464-474.
41. Chen J.F., Eltzschig H.K., Fredholm B.B. Adenosine receptors as drug targets-What are the challenges?. Nature Reviews. Drug Discovery 2013, 12:265-286.
42. Chen X., Gawryluk J.W., Wagener J.F., Ghribi O., Geiger J.D. Caffeine blocks disruption of blood brain barrier in a rabbit model of Alzheimer's disease. Journal of Neuroinflammation 2008, 5:12.
43. Chen J.F., Huang Z., Ma J., Zhu J., Moratalla R., Standaert D., et al. A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. Journal of Neuroscience 1999, 19:9192-9200.
44. Chen J.F., Xu K., Petzer J.P., Staal R., Xu Y.H., Beilstein M., et al. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. Journal of Neuroscience 2001, 21:RC143.
45. Cheng H.C., Shih H.M., Chern Y. Essential role of CREB activation by A2A adenosine receptors in rescuing the NGF-induced neurite outgrowth impaired by blockage of the MAPK cascade. Journal of Biological Chemistry 2002, 277:33930-33942.
46. Chiang M.C., Chen H.M., Lai H.L., Chen H.W., Chou S.Y., Chen C.M., et al. The A2A adenosine receptor rescues the urea cycle deficiency of Huntington's disease by enhancing the activity of the ubiquitin-proteasome system. Human Molecular Genetics 2009, 18:2929-2942.
47. Chiang M.C., Lee Y.C., Huang C.L., Chern Y. cAMP-response element-binding protein contributes to suppression of the A2A adenosine receptor promoter by mutant Huntingtin with expanded polyglutamine residues. Journal of Biological Chemistry 2005, 280:14331-14340.
48. Chiu G.S., Chatterjee D., Darmody P.T., Walsh J.P., Meling D.D., Johnson R.W., et al. Hypoxia/reoxygenation impairs memory formation via adenosine-dependent activation of caspase 1. Journal of Neuroscience 2012, 32:13945-13955.
49. Choi W.Y., Balsam P.D., Horvitz J.C. Extended habit training reduces dopamine mediation of appetitive response expression. Journal of Neuroscience 2005, 25:6729-6733.
50. Chou S.Y., Lee Y.C., Chen H.M., Chiang M.C., Lai H.L., Chang H.H., et al. CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model. Journal of Neurochemistry 2005, 93:310-320.
51. Chung H.J., Ge W.P., Qian X., Wiser O., Jan Y.N., Jan L.Y. G protein-activated inwardly rectifying potassium channels mediate depotentiation of long-term potentiation. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:635-640.
52. Ciruela F., Casado V., Rodrigues R.J., Lujan R., Burgueno J., Canals M., et al. Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers. Journal of Neuroscience 2006, 26:2080-2087.
53. Clinton S.M., Sucharski I.L., Finlay J.M. Desipramine attenuates working memory impairments induced by partial loss of catecholamines in the rat medial prefrontal cortex. Psychopharmacology 2006, 183:404-412.
54. Coccurello R., Breysse N., Amalric M. Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats. Neuropsychopharmacology 2004, 29:1451-1461.
55. Cognato G.P., Agostinho P.M., Hockemeyer J., Muller C.E., Souza D.O., Cunha R.A. Caffeine and an adenosine A(2A) receptor antagonist prevent memory impairment and synaptotoxicity in adult rats triggered by a convulsive episode in early life. Journal of Neurochemistry 2010, 112:453-462.
56. Coleman P., Federoff H., Kurlan R. A focus on the synapse for neuroprotection in Alzheimer disease and other dementias. Neurology 2004, 63:1155-1162.
57. Coric V., van Dyck C.H., Salloway S., Andreasen N., Brody M., Richter R.W., et al. Safety and tolerability of the gamma-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Archives of Neurology 2012, 69:1430-1440.
58. Costa M.S., Botton P.H., Mioranzza S., Souza D.O., Porciuncula L.O. Caffeine prevents age-associated recognition memory decline and changes brain-derived neurotrophic factor and tirosine kinase receptor (TrkB) content in mice. Neuroscience 2008, 153:1071-1078.
59. Costenla A.R., Cunha R.A., de Mendonca A. Caffeine, adenosine receptors, and synaptic plasticity. Journal of Alzheimer's Disease 2010, 20(Suppl. 1):S25-S34.
60. Costenla A.R., Diogenes M.J., Canas P.M., Rodrigues R.J., Nogueira C., Maroco J., et al. Enhanced role of adenosine A(2A) receptors in the modulation of LTP in the rat hippocampus upon ageing. European Journal of Neuroscience 2011, 34:12-21.
61. Costenla A.R., Lopes L.V., de Mendonca A., Ribeiro J.A. A functional role for adenosine A3 receptors: Modulation of synaptic plasticity in the rat hippocampus. Neuroscience Letters 2001, 302:53-57.
62. Cunha R.A. Caffeine, adenosine receptors, memory and Alzheimer disease. Medicina Clínica (Barcelona) 2008, 131:790-795.
63. Cunha R.A., Agostinho P.M. Chronic caffeine consumption prevents memory disturbance in different animal models of memory decline. Journal of Alzheimer's Disease 2010, 20(Suppl. 1):S95-S116.
64. Cunha G.M., Canas P.M., Melo C.S., Hockemeyer J., Muller C.E., Oliveira C.R., et al. Adenosine A2A receptor blockade prevents memory dysfunction caused by beta-amyloid peptides but not by scopolamine or MK-801. Experimental Neurology 2008, 210:776-781.
65. Cunha R.A., Ferre S., Vaugeois J.M., Chen J.F. Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders. Current Pharmaceutical Design 2008, 14:1512-1524.
66. Dai S.S., Li W., An J.H., Wang H., Yang N., Chen X.Y., et al. Adenosine A2A receptors in both bone marrow cells and non-bone marrow cells contribute to traumatic brain injury. Journal of Neurochemistry 2010, 113:1536-1544.
67. d'Alcantara P., Ledent C., Swillens S., Schiffmann S.N. Inactivation of adenosine A2A receptor impairs long term potentiation in the accumbens nucleus without altering basal synaptic transmission. Neuroscience 2001, 107:455-464.
68. Dall'Igna O.P., Fett P., Gomes M.W., Souza D.O., Cunha R.A., Lara D.R. Caffeine and adenosine A(2a) receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits in mice. Experimental Neurology 2007, 203:241-245.
69. Dall'lgna O.P., Porciuncula L.O., Souza D.O., Cunha R.A., Lara D.R. Neuroprotection by caffeine and adenosine A(2A) receptor blockade of beta-amyloid neurotoxicity. British Journal of Pharmacology 2003, 138:1207-1209.
70. Dayan P., Balleine B.W. Reward, motivation, and reinforcement learning. Neuron 2002, 36:285-298.
71. de Mendonca A., Ribeiro J.A. Adenosine and neuronal plasticity. Life Sciences 1997, 60:245-251.
72. Decamp E., Schneider J.S. Attention and executive function deficits in chronic low-dose MPTP-treated non-human primates. European Journal of Neuroscience 2004, 20:1371-1378.
73. Deng X., Shibata H., Ninomiya H., Tashiro N., Iwata N., Ozaki N., et al. Association study of polymorphisms in the excitatory amino acid transporter 2 gene (SLC1A2) with schizophrenia. BMC Psychiatry 2004, 4:21.
74. Dhaenens C.M., Burnouf S., Simonin C., Van Brussel E., Duhamel A., Defebvre L., et al. A genetic variation in the ADORA2A gene modifies age at onset in Huntington's disease. Neurobiology of Disease 2009, 35:474-476.
75. Dias R.B., Ribeiro J.A., Sebastiao A.M. Enhancement of AMPA currents and GluR1 membrane expression through PKA-coupled adenosine A(2A) receptors. Hippocampus 2012, 22:276-291.
76. Dias R.B., Rombo D.M., Ribeiro J.A., Henley J.M., Sebastiao A.M. Adenosine: Setting the stage for plasticity. Trends in Neurosciences 2013, 36:248-257.
77. DiFiglia M. Excitotoxic injury of the neostriatum: A model for Huntington's disease. Trends in Neurosciences 1990, 13:286-289.
78. Diogenes M.J., Fernandes C.C., Sebastiao A.M., Ribeiro J.A. Activation of adenosine A2A receptor facilitates brain-derived neurotrophic factor modulation of synaptic transmission in hippocampal slices. Journal of Neuroscience 2004, 24:2905-2913.
79. Diogenes M.J., Neves-Tome R., Fucile S., Martinello K., Scianni M., Theofilas P., et al. Homeostatic control of synaptic activity by endogenous adenosine is mediated by adenosine kinase. Cerebral Cortex 2014, 24:67-80.
80. Dixon A.K., Gubitz A.K., Sirinathsinghji D.J., Richardson P.J., Freeman T.C. Tissue distribution of adenosine receptor mRNAs in the rat. British Journal of Pharmacology 1996, 118:1461-1468.
81. Domenici M.R., Scattoni M.L., Martire A., Lastoria G., Potenza R.L., Borioni A., et al. Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice. Neurobiology of Disease 2007, 28:197-205.
82. Doody R.S., Raman R., Farlow M., Iwatsubo T., Vellas B., Joffe S., et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. New England Journal of Medicine 2013, 369:341-350.
83. Duarte J.M., Agostinho P.M., Carvalho R.A., Cunha R.A. Caffeine consumption prevents diabetes-induced memory impairment and synaptotoxicity in the hippocampus of NONcZNO10/LTJ mice. PLoS One 2012, 7:e21899.
84. Duarte J.M., Carvalho R.A., Cunha R.A., Gruetter R. Caffeine consumption attenuates neurochemical modifications in the hippocampus of streptozotocin-induced diabetic rats. Journal of Neurochemistry 2009, 111:368-379.
85. Duff K., Paulsen J., Mills J., Beglinger L.J., Moser D.J., Smith M.M., et al. Mild cognitive impairment in prediagnosed Huntington disease. Neurology 2010, 75:500-507.
86. Dunwiddie T.V., Fredholm B.B. Adenosine neuromodulation. Purinergic approaches in experimental therapeutics 1997, 359-382. Wiley-Liss, New York. M.F. Jarvis, K.A. Jacobson (Eds.).
87. Dunwiddie T.V., Masino S.A. The role and regulation of adenosine in the central nervous system. Annual Review of Neuroscience 2001, 24:31-55.
88. Ena S.L., De Backer J.F., Schiffmann S.N., de Kerchove d'Exaerde A. FACS array profiling identifies Ecto-5' nucleotidase as a striatopallidal neuron-specific gene involved in striatal-dependent learning. Journal of Neuroscience 2013, 33:8794-8809.
89. Eskelinen M.H., Ngandu T., Tuomilehto J., Soininen H., Kivipelto M. Midlife coffee and tea drinking and the risk of late-life dementia: A population-based CAIDE study. Journal of Alzheimer's Disease 2009, 16:85-91.
90. Espinosa J., Rocha A., Nunes F., Costa M.S., Schein V., Kazlauckas V., et al. Caffeine consumption prevents memory impairment, neuronal damage, and adenosine A2A receptors upregulation in the hippocampus of a rat model of sporadic dementia. Journal of Alzheimer's Disease 2013, 34:509-518.
91. Ferrante R.J., Gutekunst C.A., Persichetti F., McNeil S.M., Kowall N.W., Gusella J.F., et al. Heterogeneous topographic and cellular distribution of Huntingtin expression in the normal human neostriatum. J Neurosci 1997, 17:3052-3063.
92. Ferre S. Adenosine-dopamine interactions in the ventral striatum. Implications for the treatment of schizophrenia. Psychopharmacology 1997, 133:107-120.
93. Ferre S. An update on the mechanisms of the psychostimulant effects of caffeine. Journal of Neurochemistry 2008, 105:1067-1079.
94. Ferre S., Fredholm B.B., Morelli M., Popoli P., Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends in Neurosciences 1997, 20:482-487.
95. Ferre S., Herrera-Marschitz M., Grabowska-Anden M., Casas M., Ungerstedt U., Anden N.E. Postsynaptic dopamine/adenosine interaction: II. Postsynaptic dopamine agonism and adenosine antagonism of methylxanthines in short-term reserpinized mice. European Journal of Pharmacology 1991, 192:31-37.
96. Ferre S., Herrera-Marschitz M., Grabowska-Anden M., Ungerstedt U., Casas M., Anden N.E. Postsynaptic dopamine/adenosine interaction: I. Adenosine analogues inhibit dopamine D2-mediated behaviour in short-term reserpinized mice. European Journal of Pharmacology 1991, 192:25-30.
97. Ferre S., Karcz-Kubicha M., Hope B.T., Popoli P., Burgueno J., Gutierrez M.A., et al. Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: Implications for striatal neuronal function. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:11940-11945.
98. Ferre S., Lluis C., Justinova Z., Quiroz C., Orru M., Navarro G., et al. Adenosine-cannabinoid receptor interactions. Implications for striatal function. British Journal of Pharmacology 2010, 160:443-453.
99. Ferre S., Popoli P., Gimenez-Llort L., Rimondini R., Muller C.E., Stromberg I., et al. Adenosine/dopamine interaction: Implications for the treatment of Parkinson's disease. Parkinsonism & Related Disorders 2001, 7:235-241.
100. Ferre S., Quiroz C., Woods A.S., Cunha R., Popoli P., Ciruela F., et al. An update on adenosine A2A-dopamine D2 receptor interactions: Implications for the function of G protein-coupled receptors. Current Pharmaceutical Design 2008, 14:1468-1474.
101. Ferre S., von Euler G., Johansson B., Fredholm B.B., Fuxe K. Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. Proceedings of the National Academy of Sciences of the United States of America 1991, 88:7238-7241.
102. Field J.R., Walker A.G., Conn P.J. Targeting glutamate synapses in schizophrenia. Trends in Molecular Medicine 2011, 17:689-698.
103. Fink J.S., Weaver D.R., Rivkees S.A., Peterfreund R.A., Pollack A.E., Adler E.M., et al. Molecular cloning of the rat A2 adenosine receptor: Selective co-expression with D2 dopamine receptors in rat striatum. Brain Research. Molecular Brain Research 1992, 14:186-195.
104. Florian C., Vecsey C.G., Halassa M.M., Haydon P.G., Abel T. Astrocyte-derived adenosine and A1 receptor activity contribute to sleep loss-induced deficits in hippocampal synaptic plasticity and memory in mice. Journal of Neuroscience 2011, 31:6956-6962.
105. Fontinha B.M., Delgado-Garcia J.M., Madronal N., Ribeiro J.A., Sebastiao A.M., Gruart A. Adenosine A(2A) receptor modulation of hippocampal CA3-CA1 synapse plasticity during associative learning in behaving mice. Neuropsychopharmacology 2009, 34:1865-1874.
106. Fontinha B.M., Diogenes M.J., Ribeiro J.A., Sebastiao A.M. Enhancement of long-term potentiation by brain-derived neurotrophic factor requires adenosine A2A receptor activation by endogenous adenosine. Neuropharmacology 2008, 54:924-933.
107. Fox N.C., Black R.S., Gilman S., Rossor M.N., Griffith S.G., Jenkins L., et al. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 2005, 64:1563-1572.
108. Fredholm B., Chen J.-F., Masino S.A., Vaugeois J.-M. Actions of adenosine at its receptors in the CNS: Insights from knockouts and drugs. Annual Review of Pharmacology and Toxicology 2005, 45:385-412.
109. Fredholm B.B., Chern Y., Franco R., Sitkovsky M. Aspects of the general biology of adenosine A2A signaling. Progress in Neurobiology 2007, 83:263-276.
110. Fredholm B.B., IJzerman A., Jacobson K.A., Klotz K.N., Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacological Reviews 2001, 53:527-552.
111. Fredholm B.B., Proctor W., Van der Ploeg I., Dunwiddie T.V. In vivo pertussis toxin treatment attenuates some, but not all, adenosine A1 effects in slices of the rat hippocampus. European Journal of Pharmacology 1989, 172:249-262.
112. Fukumitsu N., Ishii K., Kimura Y., Oda K., Hashimoto M., Suzuki M., et al. Adenosine A(1) receptors using 8-dicyclopropylmethyl-1-[(11)C]methyl-3-propylxanthine PET in Alzheimer's disease 2008, 22:841-847.
113. Furtado J.M., Lansingh V.C., Carter M.J., Milanese M.F., Pena B.N., Ghersi H.A., et al. Causes of blindness and visual impairment in Latin America. Survey of Ophthalmology 2012, 57:149-177.
114. Fuxe K., Agnati L.F., Jacobsen K., Hillion J., Canals M., Torvinen M., et al. Receptor heteromerization in adenosine A2A receptor signaling: Relevance for striatal function and Parkinson's disease. Neurology 2003, 61:S19-S23.
115. Galasko D., Chang L., Motter R., Clark C.M., Kaye J., Knopman D., et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Archives of Neurology 1998, 55:937-945.
116. Gelber R.P., Petrovitch H., Masaki K.H., Ross G.W., White L.R. Coffee intake in midlife and risk of dementia and its neuropathologic correlates. Journal of Alzheimer's Disease 2011, 23:607-615.
117. Gerevich Z., Wirkner K., Illes P. Adenosine A2A receptors inhibit the N-methyl-d-aspartate component of excitatory synaptic currents in rat striatal neurons. European Journal of Pharmacology 2002, 451:161-164.
118. Gianfriddo M., Melani A., Turchi D., Giovannini M.G., Pedata F. Adenosine and glutamate extracellular concentrations and mitogen-activated protein kinases in the striatum of Huntington transgenic mice. Selective antagonism of adenosine A2A receptors reduces transmitter outflow. Neurobiology of Disease 2004, 17:77-88.
119. Gilman S., Koller M., Black R.S., Jenkins L., Griffith S.G., Fox N.C., et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005, 64:1553-1562.
120. Gimenez-Llort L., Fernandez-Teruel A., Escorihuela R.M., Fredholm B.B., Tobena A., Pekny M., et al. Mice lacking the adenosine A1 receptor are anxious and aggressive, but are normal learners with reduced muscle strength and survival rate. European Journal of Neuroscience 2002, 16:547-550.
121. Gimenez-Llort L., Masino S.A., Diao L., Fernandez-Teruel A., Tobena A., Halldner L., et al. Mice lacking the adenosine A(1) receptor have normal spatial learning and plasticity in the CA1 region of the hippocampus, but they habituate more slowly. Synapse 2005, 57:8-16.
122. Gimenez-Llort L., Schiffmann S.N., Shmidt T., Canela L., Camon L., Wassholm M., et al. Working memory deficits in transgenic rats overexpressing human adenosine A2A receptors in the brain. Neurobiology of Learning and Memory 2007, 87:42-56.
123. Goldman-Rakic P.S. Cellular basis of working memory. Neuron 1995, 14:477-485.
124. Goldman-Rakic P.S. The physiological approach: Functional architecture of working memory and disordered cognition in schizophrenia. Biological Psychiatry 1999, 46:650-661.
125. Goldman-Rakic P.S., Castner S.A., Svensson T.H., Siever L.J., Williams G.V. Targeting the dopamine D1 receptor in schizophrenia: Insights for cognitive dysfunction. Psychopharmacology 2004, 174:3-16.
126. Golembiowska K., Zylewska A. Agonists of A1 and A2A adenosine receptors attenuate methamphetamine-induced overflow of dopamine in rat striatum. Brain Research 1998, 806:202-209.
127. Gomes C.V., Kaster M.P., Tome A.R., Agostinho P.M., Cunha R.A. Adenosine receptors and brain diseases: Neuroprotection and neurodegeneration. Biochimica et Biophysica Acta 2011, 1808:1380-1399.
128. Gotham A.M., Brown R.G., Marsden C.D. 'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa. Brain 1988, 111(Pt. 2):299-321.
129. Gotoh L., Mitsuyasu H., Kobayashi Y., Oribe N., Takata A., Ninomiya H., et al. Association analysis of adenosine A1 receptor gene (ADORA1) polymorphisms with schizophrenia in a Japanese population. Psychiatric Genetics 2009, 19:328-335.
130. Graybiel A.M. Habits, rituals, and the evaluative brain. Annual Review of Neuroscience 2008, 31:359-387.
131. Gundlfinger A., Bischofberger J., Johenning F.W., Torvinen M., Schmitz D., Breustedt J. Adenosine modulates transmission at the hippocampal mossy fibre synapse via direct inhibition of presynaptic calcium channels. Journal of Physiology 2007, 582:263-277.
132. Hagena H., Manahan-Vaughan D. Frequency facilitation at mossy fiber-CA3 synapses of freely behaving rats contributes to the induction of persistent LTD via an adenosine-A1 receptor-regulated mechanism. Cerebral Cortex 2010, 20:1121-1130.
133. Halassa M.M., Florian C., Fellin T., Munoz J.R., Lee S.Y., Abel T., et al. Astrocytic modulation of sleep homeostasis and cognitive consequences of sleep loss. Neuron 2009, 61:213-219.
134. Hallock H.L., Arreola A.C., Shaw C.L., Griffin A.L. Dissociable roles of the dorsal striatum and dorsal hippocampus in conditional discrimination and spatial alternation T-maze tasks. Neurobiology of Learning and Memory 2013, 100:108-116.
135. Hameleers P.A., Van Boxtel M.P., Hogervorst E., Riedel W.J., Houx P.J., Buntinx F., et al. Habitual caffeine consumption and its relation to memory, attention, planning capacity and psychomotor performance across multiple age groups. Human Psychopharmacology 2000, 15:573-581.
136. Hansen R.T., Zhang H.T. Senescent-induced dysregulation of cAMP/CREB signaling and correlations with cognitive decline. Brain Research 2013, 1516:93-109.
137. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 2002, 297:353-356.
138. Hasuo H., Shoji S., Gallagher J.P., Akasu T. Adenosine inhibits the synaptic potentials in rat septal nucleus neurons mediated through pre- and postsynaptic A1-adenosine receptors. Neuroscience Research 1992, 13:281-299.
139. Hauser R.A., Cantillon M., Pourcher E., Micheli F., Mok V., Onofrj M., et al. Preladenant in patients with Parkinson's disease and motor fluctuations: A phase 2, double-blind, randomised trial. Lancet Neurology 2011, 10:221-229.
140. Higley M.J., Sabatini B.L. Competitive regulation of synaptic Ca2+ influx by D2 dopamine and A2A adenosine receptors. Nature Neuroscience 2010, 13:958-966.
141. Hikida T., Yawata S., Yamaguchi T., Danjo T., Sasaoka T., Wang Y., et al. Pathway-specific modulation of nucleus accumbens in reward and aversive behavior via selective transmitter receptors. Proceedings of the National Academy of Sciences of the United States of America 2013, 110:342-347.
142. Hilario M.R., Clouse E., Yin H.H., Costa R.M. Endocannabinoid signaling is critical for habit formation. Frontiers in Integrative Neuroscience 2007, 1:6.
143. Hillion J., Canals M., Torvinen M., Casado V., Scott R., Terasmaa A., et al. Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors. Journal of Biological Chemistry 2002, 277:18091-18097.
144. Hirota T., Kishi T. Adenosine hypothesis in schizophrenia and bipolar disorder: A systematic review and meta-analysis of randomized controlled trial of adjuvant purinergic modulators. Schizophrenia Research 2013, 149:88-95.
145. Ho A.K., Sahakian B.J., Brown R.G., Barker R.A., Hodges J.R., Ane M.N., et al. Profile of cognitive progression in early Huntington's disease. Neurology 2003, 61:1702-1706.
146. Hong C.J., Liu H.C., Liu T.Y., Liao D.L., Tsai S.J. Association studies of the adenosine A2a receptor (1976T>C) genetic polymorphism in Parkinson's disease and schizophrenia. Journal of Neural Transmission 2005, 112:1503-1510.
147. Hooper N., Fraser C., Stone T.W. Effects of purine analogues on spontaneous alternation in mice. Psychopharmacology 1996, 123:250-257.
148. Howard R., McShane R., Lindesay J., Ritchie C., Baldwin A., Barber R., et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. New England Journal of Medicine 2012, 366:893-903.
149. Hunter J.M., Lesort M., Johnson G.V. Ubiquitin-proteasome system alterations in a striatal cell model of Huntington's disease. Journal of Neuroscience Research 2007, 85:1774-1788.
150. Hwang Y., Kim J., Shin J.Y., Kim J.I., Seo J.S., Webster M.J., et al. Gene expression profiling by mRNA sequencing reveals increased expression of immune/inflammation-related genes in the hippocampus of individuals with schizophrenia. Translational Psychiatry 2013, 3:e321.
151. Ikeda K., Kurokawa M., Aoyama S., Kuwana Y. Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease. Journal of Neurochemistry 2002, 80:262-270.
152. Jaarsma D., Sebens J.B., Korf J. Reduction of adenosine A1-receptors in the perforant pathway terminal zone in Alzheimer hippocampus. Neuroscience Letters 1991, 121:111-114.
153. Jacobson K.A., von Lubitz D.K., Daly J.W., Fredholm B.B. Adenosine receptor ligands: Differences with acute versus chronic treatment. Trends in Pharmacological Sciences 1996, 17:108-113.
154. Jansen K.L., Faull R.L., Dragunow M., Synek B.L. Alzheimer's disease: Changes in hippocampal N-methyl-d-aspartate, quisqualate, neurotensin, adenosine, benzodiazepine, serotonin and opioid receptors-An autoradiographic study. Neuroscience 1990, 39:613-627.
155. Jenner P., Mori A., Hauser R., Morelli M., Fredholm B.B., Chen J.F. Adenosine, adenosine A 2A antagonists, and Parkinson's disease. Parkinsonism & Related Disorders 2009, 15:406-413.
156. Jeronimo-Santos A., Batalha V.L., Muller C.E., Baqi Y., Sebastiao A.M., Lopes L.V., et al. Impact of in vivo chronic blockade of adenosine A receptors on the BDNF-mediated facilitation of LTP. Neuropharmacology 2014, 83:99-106.
157. Johansson B., Halldner L., Dunwiddie T.V., Masino S.A., Poelchen W., Gimenez-Llort L., et al. Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:9407-9412.
158. Johnson A., van der Meer M.A., Redish A.D. Integrating hippocampus and striatum in decision-making. Current Opinion in Neurobiology 2007, 17:692-697.
159. Jones R.W. A review comparing the safety and tolerability of memantine with the acetylcholinesterase inhibitors. International Journal of Geriatric Psychiatry 2010, 25:547-553.
160. Julien C.L., Thompson J.C., Wild S., Yardumian P., Snowden J.S., Turner G., et al. Psychiatric disorders in preclinical Huntington's disease. Journal of Neurology, Neurosurgery and Psychiatry 2007, 78:939-943.
161. Kachroo A., Orlando L.R., Grandy D.K., Chen J.F., Young A.B., Schwarzschild M.A. Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice. Journal of Neuroscience 2005, 25:10414-10419.
162. Kachroo A., Schwarzschild M.A. Adenosine A2A receptor gene disruption protects in an alpha-synuclein model of Parkinson's disease. Annals of Neurology 2012, 71:278-282.
163. Kadowaki Horita T., Kobayashi M., Mori A., Jenner P., Kanda T. Effects of the adenosine A2A antagonist istradefylline on cognitive performance in rats with a 6-OHDA lesion in prefrontal cortex. Psychopharmacology 2013, 230:345-352.
164. Kafka S.H., Corbett R. Selective adenosine A2A receptor/dopamine D2 receptor interactions in animal models of schizophrenia. European Journal of Pharmacology 1996, 295:147-154.
165. Kamikubo Y., Shimomura T., Fujita Y., Tabata T., Kashiyama T., Sakurai T., et al. Functional cooperation of metabotropic adenosine and glutamate receptors regulates postsynaptic plasticity in the cerebellum. Journal of Neuroscience 2013, 33:18661-18671.
166. Kehagia A.A., Barker R.A., Robbins T.W. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurology 2010, 9:1200-1213.
167. Kensinger E.A., Shearer D.K., Locascio J.J., Growdon J.H., Corkin S. Working memory in mild Alzheimer's disease and early Parkinson's disease. Neuropsychology 2003, 17:230-239.
168. Kerr M.I., Wall M.J., Richardson M.J. Adenosine A1 receptor activation mediates the developmental shift at layer 5 pyramidal cell synapses and is a determinant of mature synaptic strength. Journal of Physiology 2013, 591:3371-3380.
169. Kim J., Kwon J.T., Kim H.S., Han J.H. CREB and neuronal selection for memory trace. Frontiers in Neural Circuits 2013, 7:44.
170. Kirsch G.E., Codina J., Birnbaumer L., Brown A.M. Coupling of ATP-sensitive K+channels to A1 receptors by G proteins in rat ventricular myocytes. American Journal of Physiology 1990, 259:H820-H826.
171. Kopf S.R., Melani A., Pedata F., Pepeu G. Adenosine and memory storage: Effect of A(1) and A(2) receptor antagonists. Psychopharmacology 1999, 146:214-219.
172. Kreitzer A.C., Malenka R.C. Dopamine modulation of state-dependent endocannabinoid release and long-term depression in the striatum. Journal of Neuroscience 2005, 25:10537-10545.
173. Kreitzer A.C., Malenka R.C. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature 2007, 445:643-647.
174. Kukley M., Schwan M., Fredholm B.B., Dietrich D. The role of extracellular adenosine in regulating mossy fiber synaptic plasticity. Journal of Neuroscience 2005, 25:2832-2837.
175. Lang U.E., Lang F., Richter K., Vallon V., Lipp H.P., Schnermann J., et al. Emotional instability but intact spatial cognition in adenosine receptor 1 knock out mice. Behavioural Brain Research 2003, 145:179-188.
176. Lange K.W., Robbins T.W., Marsden C.D., James M., Owen A.M., Paul G.M. l-DOPA withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology 1992, 107:394-404.
177. Lara D.R., Dall'Igna O.P., Ghisolfi E.S., Brunstein M.G. Involvement of adenosine in the neurobiology of schizophrenia and its therapeutic implications. Progress in Neuropsychopharmacology and Biological Psychiatry 2006, 30:617-629.
178. Lawrence A.D., Hodges J.R., Rosser A.E., Kershaw A., ffrench-Constant C., Rubinsztein D.C., et al. Evidence for specific cognitive deficits in preclinical Huntington's disease. Brain 1998, 121(Pt. 7):1329-1341.
179. Lawrence A.D., Weeks R.A., Brooks D.J., Andrews T.C., Watkins L.H., Harding A.E., et al. The relationship between striatal dopamine receptor binding and cognitive performance in Huntington's disease. Brain 1998, 121(Pt. 7):1343-1355.
180. Lee F.S., Chao M.V. Activation of Trk neurotrophin receptors in the absence of neurotrophins. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:3555-3560.
181. Leite M.R., Wilhelm E.A., Jesse C.R., Brandao R., Nogueira C.W. Protective effect of caffeine and a selective A2A receptor antagonist on impairment of memory and oxidative stress of aged rats. Experimental Gerontology 2011, 46:309-315.
182. Lemere C.A., Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy?. Nature Reviews. Neurology 2010, 6:108-119.
183. Lerner T.N., Horne E.A., Stella N., Kreitzer A.C. Endocannabinoid signaling mediates psychomotor activation by adenosine A2A antagonists. Journal of Neuroscience 2010, 30:2160-2164.
184. Lerner T.N., Kreitzer A.C. RGS4 is required for dopaminergic control of striatal LTD and susceptibility to parkinsonian motor deficits. Neuron 2012, 73:347-359.
185. Lewis S.J., Dove A., Robbins T.W., Barker R.A., Owen A.M. Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry. Journal of Neuroscience 2003, 23:6351-6356.
186. Li J.Y., Plomann M., Brundin P. Huntington's disease: A synaptopathy?. Trends in Molecular Medicine 2003, 9:414-420.
187. Liljeholm M., O'Doherty J.P. Contributions of the striatum to learning, motivation, and performance: An associative account. Trends in Cognitive Science 2012, 16:467-475.
188. Lim H.K., Juh R., Pae C.U., Lee B.T., Yoo S.S., Ryu S.H., et al. Altered verbal working memory process in patients with Alzheimer's disease: An fMRI investigation. Neuropsychobiology 2008, 57:181-187.
189. Lindsay J., Laurin D., Verreault R., Hebert R., Helliwell B., Hill G.B., et al. Risk factors for Alzheimer's disease: A prospective analysis from the Canadian Study of Health and Aging. American Journal of Epidemiology 2002, 156:445-453.
190. Lisman J.E., Coyle J.T., Green R.W., Javitt D.C., Benes F.M., Heckers S., et al. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends in Neurosciences 2008, 31:234-242.
191. Litvan I., Aarsland D., Adler C.H., Goldman J.G., Kulisevsky J., Mollenhauer B., et al. MDS Task Force on mild cognitive impairment in Parkinson's disease: Critical review of PD-MCI. Movement Disorders 2011, 26:1814-1824.
192. Londos C., Cooper D.M., Wolff J. Subclasses of external adenosine receptors. Proceedings of the National Academy of Sciences of the United States of America 1980, 77:2551-2554.
193. Lopes L.V., Cunha R.A., Ribeiro J.A. Cross talk between A(1) and A(2A) adenosine receptors in the hippocampus and cortex of young adult and old rats. Journal of Neurophysiology 1999, 82:3196-3203.
194. Lovinger D.M., Choi S. Activation of adenosine A1 receptors initiates short-term synaptic depression in rat striatum. Neuroscience Letters 1995, 199:9-12.
195. Lu G., Zhou Q.X., Kang S., Li Q.L., Zhao L.C., Chen J.D., et al. Chronic morphine treatment impaired hippocampal long-term potentiation and spatial memory via accumulation of extracellular adenosine acting on adenosine A1 receptors. Journal of Neuroscience 2010, 30:5058-5070.
196. Lynch M.A., Errington M.L., Clements M.P., Bliss T.V., Redini-Del Negro C., Laroche S. Increases in glutamate release and phosphoinositide metabolism associated with long-term potentiation and classical conditioning. Progress in Brain Research 1990, 83:251-256.
197. Maggi L., Trettel F., Scianni M., Bertollini C., Eusebi F., Fredholm B.B., et al. LTP impairment by fractalkine/CX3CL1 in mouse hippocampus is mediated through the activity of adenosine receptor type 3 (A3R). Journal of Neuroimmunology 2009, 215:36-42.
198. Marquez-Ruiz J., Leal-Campanario R., Sanchez-Campusano R., Molaee-Ardekani B., Wendling F., Miranda P.C., et al. Transcranial direct-current stimulation modulates synaptic mechanisms involved in associative learning in behaving rabbits. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:6710-6715.
199. Martin J.B., Gusella J.F. Huntington's disease. Pathogenesis and management. New England Journal of Medicine 1986, 315:1267-1276.
200. Matos M., Augusto E., Agostinho P., Cunha R.A., Chen J.F. Antagonistic interaction between adenosine A2A receptors and Na+/K+-ATPase-alpha2 controlling glutamate uptake in astrocytes. Journal of Neuroscience 2013, 33:18492-18502.
201. Matos M., Augusto E., Santos-Rodrigues A.D., Schwarzschild M.A., Chen J.F., Cunha R.A., et al. Adenosine A(2A) receptors modulate glutamate uptake in cultured astrocytes and gliosomes. Glia 2012, 60:702-716.
202. Mattsson N., Zetterberg H., Hansson O., Andreasen N., Parnetti L., Jonsson M., et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009, 302:385-393.
203. Matute C., Melone M., Vallejo-Illarramendi A., Conti F. Increased expression of the astrocytic glutamate transporter GLT-1 in the prefrontal cortex of schizophrenics. Glia 2005, 49:451-455.
204. Melani A., Cipriani S., Vannucchi M.G., Nosi D., Donati C., Bruni P., et al. Selective adenosine A2a receptor antagonism reduces JNK activation in oligodendrocytes after cerebral ischaemia. Brain 2009, 132:1480-1495.
205. Melani A., Gianfriddo M., Vannucchi M.G., Cipriani S., Baraldi P.G., Giovannini M.G., et al. The selective A2A receptor antagonist SCH 58261 protects from neurological deficit, brain damage and activation of p38 MAPK in rat focal cerebral ischemia. Brain Research 2006, 1073-1074:470-480.
206. Mihara T., Mihara K., Yarimizu J., Mitani Y., Matsuda R., Yamamoto H., et al. Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson's disease and cognition. Journal of Pharmacology and Experimental Therapeutics 2007, 323:708-719.
207. Miller B.R., Walker A.G., Shah A.S., Barton S.J., Rebec G.V. Dysregulated information processing by medium spiny neurons in striatum of freely behaving mouse models of Huntington's disease. Journal of Neurophysiology 2008, 100:2205-2216.
208. Moghaddam B., Javitt D. From revolution to evolution: The glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 2012, 37:4-15.
209. Moore K.A., Nicoll R.A., Schmitz D. Adenosine gates synaptic plasticity at hippocampal mossy fiber synapses. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:14397-14402.
210. Mori A., Shindou T. Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: A potential mechanism for the antiparkinsonian effects of A2A antagonists. Neurology 2003, 61:S44-S48.
211. Munoz L., Ammit A.J. Targeting p38 MAPK pathway for the treatment of Alzheimer's disease. Neuropharmacology 2010, 58:561-568.
212. Munoz-Sanjuan I., Bates G.P. The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease. Journal of Clinical Investigation 2011, 121:476-483.
213. Murray C.J., Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: Global burden of disease study. Lancet 1997, 349:1498-1504.
214. Nam H.W., Hinton D.J., Kang N.Y., Kim T., Lee M.R., Oliveros A., et al. Adenosine transporter ENT1 regulates the acquisition of goal-directed behavior and ethanol drinking through A2A receptor in the dorsomedial striatum. Journal of Neuroscience 2013, 33:4329-4338.
215. Norenberg W., Wirkner K., Assmann H., Richter M., Illes P. Adenosine A2A receptors inhibit the conductance of NMDA receptor channels in rat neostriatal neurons. Amino Acids 1998, 14:33-39.
216. Norenberg W., Wirkner K., Illes P. Effect of adenosine and some of its structural analogues on the conductance of NMDA receptor channels in a subset of rat neostriatal neurones. British Journal of Pharmacology 1997, 122:71-80.
217. Ohno M., Watanabe S. Working memory failure by stimulation of hippocampal adenosine A1 receptors in rats. Neuroreport 1996, 7:3013-3016.
218. Olesen J., Gustavsson A., Svensson M., Wittchen H.U., Jonsson B. The economic cost of brain disorders in Europe. European Journal of Neurology 2012, 19:155-162.
219. O'Neill M., Brown V.J. Amphetamine and the adenosine A(2A) antagonist KW-6002 enhance the effects of conditional temporal probability of a stimulus in rats. Behavioral Neuroscience 2007, 121:535-542.
220. O'Neill M., Brown V.J. The effect of striatal dopamine depletion and the adenosine A2A antagonist KW-6002 on reversal learning in rats. Neurobiology of Learning and Memory 2007, 88:75-81.
221. Ongini E., Fredholm B.B. Pharmacology of adenosine A2A receptors. Trends in Pharmacological Sciences 1996, 17:364-372.
222. Pan B., Hillard C.J., Liu Q.S. D2 dopamine receptor activation facilitates endocannabinoid-mediated long-term synaptic depression of GABAergic synaptic transmission in midbrain dopamine neurons via cAMP-protein kinase A signaling. Journal of Neuroscience 2008, 28:14018-14030.
223. Papp K.V., Kaplan R.F., Snyder P.J. Biological markers of cognition in prodromal Huntington's disease: A review. Brain and Cognition 2011, 77:280-291.
224. Pennartz C.M., Ito R., Verschure P.F., Battaglia F.P., Robbins T.W. The hippocampal-striatal axis in learning, prediction and goal-directed behavior. Trends in Neurosciences 2011, 34:548-559.
225. Pereira G.S., Rossato J.I., Sarkis J.J., Cammarota M., Bonan C.D., Izquierdo I. Activation of adenosine receptors in the posterior cingulate cortex impairs memory retrieval in the rat. Neurobiology of Learning and Memory 2005, 83:217-223.
226. Piccinin S., Di Angelantonio S., Piccioni A., Volpini R., Cristalli G., Fredholm B.B., et al. CX3CL1-induced modulation at CA1 synapses reveals multiple mechanisms of EPSC modulation involving adenosine receptor subtypes. Journal of Neuroimmunology 2010, 224:85-92.
227. Pierri M., Vaudano E., Sager T., Englund U. KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse. Neuropharmacology 2005, 48:517-524.
228. Piray P. The role of dorsal striatal D2-like receptors in reversal learning: A reinforcement learning viewpoint. Journal of Neuroscience 2011, 31:14049-14050.
229. Poo M.M. Neurotrophins as synaptic modulators. Nature Review Neuroscience 2001, 2:24-32.
230. Popoli P., Pezzola A., de Carolis A.S. Modulation of striatal adenosine A1 and A2 receptors induces rotational behaviour in response to dopaminergic stimulation in intact rats. European Journal of Pharmacology 1994, 257:21-25.
231. Popoli P., Pintor A., Domenici M.R., Frank C., Tebano M.T., Pezzola A., et al. Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: Possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum. Journal of Neuroscience 2002, 22:1967-1975.
232. Popoli P., Reggio R., Pezzola A., Fuxe K., Ferre S. Adenosine A1 and A2A receptor antagonists stimulate motor activity: Evidence for an increased effectiveness in aged rats. Neuroscience Letters 1998, 251:201-204.
233. Prediger R.D., Batista L.C., Takahashi R.N. Caffeine reverses age-related deficits in olfactory discrimination and social recognition memory in rats. Involvement of adenosine A1 and A2A receptors. Neurobiology of Aging 2005, 26:957-964.
234. Prediger R.D., Fernandes D., Takahashi R.N. Blockade of adenosine A2A receptors reverses short-term social memory impairments in spontaneously hypertensive rats. Behavioural Brain Research 2005, 159:197-205.
235. Prediger R.D., Pamplona F.A., Fernandes D., Takahashi R.N. Caffeine improves spatial learning deficits in an animal model of attention deficit hyperactivity disorder (ADHD)-The spontaneously hypertensive rat (SHR). International Journal of Neuropsychopharmacology 2005, 8:583-594.
236. Prediger R.D., Takahashi R.N. Modulation of short-term social memory in rats by adenosine A1 and A(2A) receptors. Neuroscience Letters 2005, 376:160-165.
237. Quiroz C., Gomes C., Pak A.C., Ribeiro J.A., Goldberg S.R., Hope B.T., et al. Blockade of adenosine A2A receptors prevents protein phosphorylation in the striatum induced by cortical stimulation. Journal of Neuroscience 2006, 26:10808-10812.
238. Randall P.A., Nunes E.J., Janniere S.L., Stopper C.M., Farrar A.M., Sager T.N., et al. Stimulant effects of adenosine antagonists on operant behavior: Differential actions of selective A2A and A1 antagonists. Psychopharmacology 2011, 216:173-186.
239. Ranganath C., Minzenberg M.J., Ragland J.D. The cognitive neuroscience of memory function and dysfunction in schizophrenia. Biological Psychiatry 2008, 64:18-25.
240. Rebola N., Lujan R., Cunha R.A., Mulle C. Adenosine A2A receptors are essential for long-term potentiation of NMDA-EPSCs at hippocampal mossy fiber synapses. Neuron 2008, 57:121-134.
241. Rebola N., Rodrigues R.J., Lopes L.V., Richardson P.J., Oliveira C.R., Cunha R.A. Adenosine A1 and A2A receptors are co-expressed in pyramidal neurons and co-localized in glutamatergic nerve terminals of the rat hippocampus. Neuroscience 2005, 133:79-83.
242. Reiner A., Albin R.L., Anderson K.D., D'Amato C.J., Penney J.B., Young A.B. Differential loss of striatal projection neurons in Huntington disease. Proceedings of the National Academy of Sciences of the United States of America 1988, 85:5733-5737.
243. Reppert S.M., Weaver D.R., Stehle J.H., Rivkees S.A. Molecular cloning and characterization of a rat A1-adenosine receptor that is widely expressed in brain and spinal cord. Molecular Endocrinology 1991, 5:1037-1048.
244. Ribeiro J.A. Adenosine A2A receptor interactions with receptors for other neurotransmitters and neuromodulators. European Journal of Pharmacology 1999, 375:101-113.
245. Ribeiro J.A., Sebastiao A.M., de Mendonca A. Adenosine receptors in the nervous system: Pathophysiological implications. Progress in Neurobiology 2002, 68:377-392.
246. Richard I.H., Justus A.W., Greig N.H., Marshall F., Kurlan R. Worsening of motor function and mood in a patient with Parkinson's disease after pharmacologic challenge with oral rivastigmine. Clinical Neuropharmacology 2002, 25:296-299.
247. Riemenschneider M., Lautenschlager N., Wagenpfeil S., Diehl J., Drzezga A., Kurz A. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Archives of Neurology 2002, 59:1729-1734.
248. Rimondini R., Ferre S., Ogren S.O., Fuxe K. Adenosine A2A agonists: A potential new type of atypical antipsychotic. Neuropsychopharmacology 1997, 17:82-91.
249. Ritchie K., Carrière I., Portet F., de Mendonca A., Dartigues J.F., Rouaud O., et al. The neuro-protective effects of caffeine: A prospective population study (the Three City Study). Neurology 2007, 69:536-545.
250. Rodrigues R.J., Alfaro T.M., Rebola N., Oliveira C.R., Cunha R.A. Co-localization and functional interaction between adenosine A(2A) and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum. Journal of Neurochemistry 2005, 92:433-441.
251. Rosenblatt A. Neuropsychiatry of Huntington's disease. Dialogues in Clinical Neuroscience 2007, 9:191-197.
252. Rosin D.L., Hettinger B.D., Lee A., Linden J. Anatomy of adenosine A2A receptors in brain: Morphological substrates for integration of striatal function. Neurology 2003, 61:S12-S18.
253. Ross G.W., Abbott R.D., Petrovitch H., Morens D.M., Grandinetti A., Tung K.H., et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 2000, 283:2674-2679.
254. Ross C.A., Margolis R.L., Reading S.A., Pletnikov M., Coyle J.T. Neurobiology of schizophrenia. Neuron 2006, 52:139-153.
255. Rouaux C., Loeffler J.P., Boutillier A.L. Targeting CREB-binding protein (CBP) loss of function as a therapeutic strategy in neurological disorders. Biochemical Pharmacology 2004, 68:1157-1164.
256. Rubaj A., Zgodzinski W., Sieklucka-Dziuba M. The influence of adenosine A3 receptor agonist: IB-MECA, on scopolamine- and MK-801-induced memory impairment. Behavioural Brain Research 2003, 141:11-17.
257. Saaksjarvi K., Knekt P., Rissanen H., Laaksonen M.A., Reunanen A., Mannisto S. Prospective study of coffee consumption and risk of Parkinson's disease. European Journal of Clinical Nutrition 2007, 62:908-915.
258. Sakamoto K., Karelina K., Obrietan K. CREB: A multifaceted regulator of neuronal plasticity and protection. Journal of Neurochemistry 2011, 116:1-9.
259. Sawamoto N., Piccini P., Hotton G., Pavese N., Thielemans K., Brooks D.J. Cognitive deficits and striato-frontal dopamine release in Parkinson's disease. Brain 2008, 131:1294-1302.
260. Scanziani M., Capogna M., Gahwiler B.H., Thompson S.M. Presynaptic inhibition of miniature excitatory synaptic currents by baclofen and adenosine in the hippocampus. Neuron 1992, 9:919-927.
261. Scheff S.W., Price D.A., Schmitt F.A., DeKosky S.T., Mufson E.J. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology 2007, 68:1501-1508.
262. Schiffmann S.N., Fisone G., Moresco R., Cunha R.A., Ferre S. Adenosine A2A receptors and basal ganglia physiology. Progress in Neurobiology 2007, 83:277-292.
263. Schiffmann S.N., Vanderhaeghen J.J. Adenosine A2 receptors regulate the gene expression of striatopallidal and striatonigral neurons. Journal of Neuroscience 1993, 13:1080-1087.
264. Schotanus S.M., Fredholm B.B., Chergui K. NMDA depresses glutamatergic synaptic transmission in the striatum through the activation of adenosine A1 receptors: Evidence from knockout mice. Neuropharmacology 2006, 51:272-282.
265. Schulte G., Fredholm B.B. Signalling from adenosine receptors to mitogen-activated protein kinases. Cellular Signalling 2003, 15:813-827.
266. Scimeca J.M., Badre D. Striatal contributions to declarative memory retrieval. Neuron 2012, 75:380-392.
267. Sebastiao A.M., Ribeiro J.A. Adenosine A2 receptor-mediated excitatory actions on the nervous system. Progress in Neurobiology 1996, 48:167-189.
268. Sebastiao A.M., Ribeiro J.A. Fine-tuning neuromodulation by adenosine. Trends in Pharmacological Sciences 2000, 21:341-346.
269. Selkoe D.J. Alzheimer's disease is a synaptic failure. Science 2002, 298:789-791.
270. Selley M.L. Increased homocysteine and decreased adenosine formation in Alzheimer's disease. Neurological Research 2004, 26:554-557.
271. Seo H., Sonntag K.C., Isacson O. Generalized brain and skin proteasome inhibition in Huntington's disease. Annals of Neurology 2004, 56:319-328.
272. Shen H.Y., Coelho J.E., Ohtsuka N., Canas P.M., Day Y.J., Huang Q.Y., et al. A critical role of the adenosine A2A receptor in extrastriatal neurons in modulating psychomotor activity as revealed by opposite phenotypes of striatum and forebrain A2A receptor knock-outs. Journal of Neuroscience 2008, 28:2970-2975.
273. Shen W., Flajolet M., Greengard P., Surmeier D.J. Dichotomous dopaminergic control of striatal synaptic plasticity. Science 2008, 321:848-851.
274. Shen H.Y., Singer P., Lytle N., Wei C.J., Lan J.Q., Williams-Karnesky R.L., et al. Adenosine augmentation ameliorates psychotic and cognitive endophenotypes of schizophrenia. Journal of Clinical Investigation 2012, 122:2567-2577.
275. Shohamy D., Myers C.E., Grossman S., Sage J., Gluck M.A., Poldrack R.A. Cortico-striatal contributions to feedback-based learning: Converging data from neuroimaging and neuropsychology. Brain 2004, 127:851-859.
276. Simoes A.P., Duarte J.A., Agasse F., Canas P.M., Tome A.R., Agostinho P., et al. Blockade of adenosine A2A receptors prevents interleukin-1beta-induced exacerbation of neuronal toxicity through a p38 mitogen-activated protein kinase pathway. Journal of Neuroinflammation 2012, 9:204.
277. Simpson E.H., Kellendonk C., Kandel E. A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. Neuron 2010, 65:585-596.
278. Singer P., Wei C.J., Chen J.F., Boison D., Yee B.K. Deletion of striatal adenosine A(2A) receptor spares latent inhibition and prepulse inhibition but impairs active avoidance learning. Behavioural Brain Research 2013, 242:54-61.
279. Snyder S.H. The dopamine hypothesis of schizophrenia: Focus on the dopamine receptor. The American Journal of Psychiatry 1976, 133:197-202.
280. Solinas M., Ferre S., You Z.B., Karcz-Kubicha M., Popoli P., Goldberg S.R. Caffeine induces dopamine and glutamate release in the shell of the nucleus accumbens. Journal of Neuroscience 2002, 22:6321-6324.
281. Spangaro M., Bosia M., Zanoletti A., Bechi M., Cocchi F., Pirovano A., et al. Cognitive dysfunction and glutamate reuptake: Effect of EAAT2 polymorphism in schizophrenia. Neuroscience Letters 2012, 522:151-155.
282. Starling A.J., Andre V.M., Cepeda C., de Lima M., Chandler S.H., Levine M.S. Alterations in N-methyl-d-aspartate receptor sensitivity and magnesium blockade occur early in development in the R6/2 mouse model of Huntington's disease. Journal of Neuroscience Research 2005, 82:377-386.
283. Stout J.C., Paulsen J.S., Queller S., Solomon A.C., Whitlock K.B., Campbell J.C., et al. Neurocognitive signs in prodromal Huntington disease. Neuropsychology 2011, 25:1-14.
284. Taylor A.E., Saint-Cyr J.A., Lang A.E. Parkinson's disease. Cognitive changes in relation to treatment response. Brain 1987, 110(Pt. 1):35-51.
285. Tebano M.T., Martire A., Chiodi V., Pepponi R., Ferrante A., Domenici M.R., et al. Adenosine A2A receptors enable the synaptic effects of cannabinoid CB1 receptors in the rodent striatum. Journal of Neurochemistry 2009, 110:1921-1930.
286. Tebano M.T., Martire A., Potenza R.L., Gro C., Pepponi R., Armida M., et al. Adenosine A(2A) receptors are required for normal BDNF levels and BDNF-induced potentiation of synaptic transmission in the mouse hippocampus. Journal of Neurochemistry 2008, 104:279-286.
287. Tebano M.T., Martire A., Rebola N., Pepponi R., Domenici M.R., Gro M.C., et al. Adenosine A2A receptors and metabotropic glutamate 5 receptors are co-localized and functionally interact in the hippocampus: A possible key mechanism in the modulation of N-methyl-d-aspartate effects. Journal of Neurochemistry 2005, 95:1188-1200.
288. Tebano M.T., Pintor A., Frank C., Domenici M.R., Martire A., Pepponi R., et al. Adenosine A2A receptor blockade differentially influences excitotoxic mechanisms at pre- and postsynaptic sites in the rat striatum. Journal of Neuroscience Research 2004, 77:100-107.
289. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993, 72:971-983.
290. Thomas G.M., Huganir R.L. MAPK cascade signalling and synaptic plasticity. Nature Review Neuroscience 2004, 5:173-183.
291. Todd K.J., Darabid H., Robitaille R. Perisynaptic glia discriminate patterns of motor nerve activity and influence plasticity at the neuromuscular junction. Journal of Neuroscience 2010, 30:11870-11882.
292. Ulas J., Brunner L.C., Nguyen L., Cotman C.W. Reduced density of adenosine A1 receptors and preserved coupling of adenosine A1 receptors to G proteins in Alzheimer hippocampus: A quantitative autoradiographic study. Neuroscience 1993, 52:843-854.
293. Uriguen L., Garcia-Fuster M.J., Callado L.F., Morentin B., La Harpe R., Casado V., et al. Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: Effect of antipsychotic treatment. Psychopharmacology 2009, 206:313-324.
294. van Boxtel M.P., Schmitt J.A., Bosma H., Jolles J. The effects of habitual caffeine use on cognitive change: A longitudinal perspective. Pharmacology, Biochemistry, and Behavior 2003, 75:921-927.
295. van Calker D., Muller M., Hamprecht B. Adenosine inhibits the accumulation of cyclic AMP in cultured brain cells. Nature 1978, 276:839-841.
296. van der Meer M.A., Redish A.D. Ventral striatum: A critical look at models of learning and evaluation. Current Opinion in Neurobiology 2011, 21:387-392.
297. van Gelder B.M., Buijsse B., Tijhuis M., Kalmijn S., Giampaoli S., Nissinen A., et al. Coffee consumption is inversely associated with cognitive decline in elderly European men: The FINE Study. European Journal of Clinical Nutrition 2007, 61:226-232.
298. van Laar T., De Deyn P.P., Aarsland D., Barone P., Galvin J.E. Effects of cholinesterase inhibitors in Parkinson's disease dementia: A review of clinical data. CNS Neuroscience and Therapeutics 2011, 17:428-441.
299. van Os J., Kapur S. Schizophrenia. Lancet 2009, 374:635-645.
300. Vila-Luna S., Cabrera-Isidoro S., Vila-Luna L., Juarez-Diaz I., Bata-Garcia J.L., Alvarez-Cervera F.J., et al. Chronic caffeine consumption prevents cognitive decline from young to middle age in rats, and is associated with increased length, branching, and spine density of basal dendrites in CA1 hippocampal neurons. Neuroscience 2012, 202:384-395.
301. Villar-Menendez I., Diaz-Sanchez S., Blanch M., Albasanz J.L., Pereira-Veiga T., Monje A., et al. Reduced striatal adenosine A2A receptor levels define a molecular subgroup in schizophrenia. Journal of Psychiatric Research 2014, 51:49-59.
302. Von Lubitz D.K., Paul I.A., Bartus R.T., Jacobson K.A. Effects of chronic administration of adenosine A1 receptor agonist and antagonist on spatial learning and memory. European Journal of Pharmacology 1993, 249:271-280.
303. Vonsattel J.P., DiFiglia M. Huntington disease. Journal of Neuropathology and Experimental Neurology 1998, 57:369-384.
304. Walker A.G., Miller B.R., Fritsch J.N., Barton S.J., Rebec G.V. Altered information processing in the prefrontal cortex of Huntington's disease mouse models. Journal of Neuroscience 2008, 28:8973-8982.
305. Walsh D.M., Selkoe D.J. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004, 44:181-193.
306. Wan Q., Yao H., Wang F. Involvement of K(+) channels in the inhibitory effects of adenosine on anoxia-induced [Ca(2+)](i) increase in cultured rat hippocampal CA1 neurons. Biological Signals and Receptors 1999, 8:309-315.
307. Wang J.H., Ma Y.Y., van den Buuse M. Improved spatial recognition memory in mice lacking adenosine A2A receptors. Experimental Neurology 2006, 199:438-445.
308. Wang J., Wang C.-E., Orr A., Tydlacka S., Li S.-H., Li X.-J. Impaired ubiquitin-proteasome system activity in the synapses of Huntington's disease mice. Journal of Cell Biology 2008, 180:1177-1189.
309. Watson G.S., Leverenz J.B. Profile of cognitive impairment in Parkinson's disease. Brain Pathology 2010, 20:640-645.
310. Wei C.J., Augusto E., Gomes C.A., Singer P., Wang Y., Boison D., et al. Regulation of fear responses by striatal and extrastriatal adenosine A receptors in forebrain. Biological Psychiatry 2013, 75:855-863.
311. Wei C.J., Singer P., Coelho J., Boison D., Feldon J., Yee B.K., et al. Selective inactivation of adenosine A(2A) receptors in striatal neurons enhances working memory and reversal learning. Learning and Memory 2011, 18:459-474.
312. Whitehead A., Perdomo C., Pratt R.D., Birks J., Wilcock G.K., Evans J.G. Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: A meta-analysis of individual patient data from randomised controlled trials. International Journal of Geriatric Psychiatry 2004, 19:624-633.
313. Wimo A., Jonsson L., Bond J., Prince M., Winblad B. The worldwide economic impact of dementia 2010. Alzheimer's & Dementia 2013, 9(1-11):e13.
314. Winblad B., Andreasen N., Minthon L., Floesser A., Imbert G., Dumortier T., et al. Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer's disease: Randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurology 2012, 11:597-604.
315. Wirkner K., Assmann H., Koles L., Gerevich Z., Franke H., Norenberg W., et al. Inhibition by adenosine A(2A) receptors of NMDA but not AMPA currents in rat neostriatal neurons. British Journal of Pharmacology 2000, 130:259-269.
316. Wonodi I., Gopinath H.V., Liu J., Adami H., Hong L.E., Allen-Emerson R., et al. Dipyridamole monotherapy in schizophrenia: Pilot of a novel treatment approach by modulation of purinergic signaling. Psychopharmacology 2011, 218:341-345.
317. Wu L.G., Saggau P. Adenosine inhibits evoked synaptic transmission primarily by reducing presynaptic calcium influx in area CA1 of hippocampus. Neuron 1994, 12:1139-1148.
318. Xia J., Chen F., Ye J., Yan J., Wang H., Duan S., et al. Activity-dependent release of adenosine inhibits the glutamatergic synaptic transmission and plasticity in the hypothalamic hypocretin/orexin neurons. Neuroscience 2009, 162:980-988.
319. Xia Z., Storm D.R. Role of signal transduction crosstalk between adenylyl cyclase and MAP kinase in hippocampus-dependent memory. Learning and Memory 2012, 19:369-374.
320. Xu K., Xu Y.H., Chen J.F., Schwarzschild M.A. Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice. Neuroscience Letters 2002, 322:13-16.
321. Yee B.K., Singer P., Chen J.F., Feldon J., Boison D. Transgenic overexpression of adenosine kinase in brain leads to multiple learning impairments and altered sensitivity to psychomimetic drugs. European Journal of Neuroscience 2007, 26:3237-3252.
322. Yee B.K., Zhu S.W., Mohammed A.H., Feldon J. Levels of neurotrophic factors in the hippocampus and amygdala correlate with anxiety- and fear-related behaviour in C57BL6 mice. Journal of Neural Transmission 2007, 114:431-444.
323. Yin H.H., Knowlton B.J. The role of the basal ganglia in habit formation. Nature Review Neuroscience 2006, 7:464-476.
324. Young A.B. Huntingtin in health and disease. Journal of Clinical Investigation 2003, 111:299-302.
325. Yu C., Gupta J., Chen J.F., Yin H.H. Genetic deletion of A2A adenosine receptors in the striatum selectively impairs habit formation. Journal of Neuroscience 2009, 29:15100-15103.
326. Zeron M.M., Hansson O., Chen N., Wellington C.L., Leavitt B.R., Brundin P., et al. Increased sensitivity to N-methyl-d-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 2002, 33:849-860.
327. Zhang J., Abdallah C.G., Wang J., Wan X., Liang C., Jiang L., et al. Upregulation of adenosine A2A receptors induced by atypical antipsychotics and its correlation with sensory gating in schizophrenia patients. Psychiatry Research 2012, 200:126-132.
328. Zhou H., Cao F., Wang Z., Yu Z.-X., Nguyen H.-P., Evans J., et al. Huntingtin forms toxic NH2-terminal fragment complexes that are promoted by the age-dependent decrease in proteasome activity. Journal of Cell Biology 2003, 163:109-118.
329. Zhou S.J., Zhu M.E., Shu D., Du X.P., Song X.H., Wang X.T., et al. Preferential enhancement of working memory in mice lacking adenosine A(2A) receptors. Brain Research 2009, 1303:74-83.
330. Zuccato C., Ciammola A., Rigamonti D., Leavitt B.R., Goffredo D., Conti L., et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001, 293:493-498.
331. Zuccato C., Tartari M., Crotti A., Goffredo D., Valenza M., Conti L., et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nature Genetics 2003, 35:76-83.
332. Zuccato C., Valenza M., Cattaneo E. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiological Reviews 2010, 90:905-981.
333. Davies S.W., Turmaine M., Cozens B.A., DiFiglia M., Sharp A.H., Ross C.A., et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997, 90:537-548.
334. DiFiglia M., Sapp E., Chase K.O., Davies S.W., Bates G.P., Vonsattel J.P., et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997, 277:1990-1993.
335. Gutekunst C.A., Levey A.I., Heilman C.J., Whaley W.L., Yi H., Nash N.R., et al. Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodies. Proceedings of the National Academy of Sciences of the United States of America 1995, 92:8710-8714.
336. Sapp E., Schwarz C., Chase K., Bhide P.G., Young A.B., Penney J., et al. Huntingtin localization in brains of normal and Huntington's disease patients. Annals of Neurology 1997, 42:604-612.